Clinicopathological and inflammatory prognostic factors in non-small cell lung cancer

Abstract

Lung cancer is the most common cause of cancer death worldwide. Despite improvements in diagnosis and treatments, the overall prognosis for patients with lung cancer remains poor and novel therapeutic approaches are required. Molecular assessments of tumour material and blood from non-small cell lung cancer (NSCLC) patients may help identify different prognostic and predictive subgroups. Recent publications suggest that biomarker profiles constructed from patient series with long and accurate follow-up outperform standard pathologic TNM staging in estimating risk of disease recurrence. The impact of neoadjuvant treatments on host immune response remains poorly characterised.